IONETIX Corporation is a leading brand in the field of healthcare technology, specifically in the areas of cardiology and radiology/nuclear medicine. They offer a range of products and services that are designed to benefit health systems, hospitals, and cardiology and radiology/nuclear medicine practice groups. One of their notable offerings is N-13 Ammonia, which is a PET imaging agent utilized for the accurate detection of CAD (coronary artery disease).

IONETIX has developed the world's first commercial compact superconducting cyclotron, called the ION-12SC, which is used to produce N-13 Ammonia. They are actively establishing a network of ION-12SCs near PET programs across the country, making this critical tracer accessible and affordable to providers through a pay-by-the-dose model. Additionally, IONETIX is also leveraging its growing network of radiopharmaceutical manufacturing locations to support the development and commercialization of targeted alpha therapy (TAT).

TAT is an emerging cancer therapy that delivers high-energy alpha particles to cancer cells, effectively treating cancer while preserving healthy tissue. IONETIX Corporation is committed to designing, manufacturing, and supporting safe and effective radiopharmaceutical products while exceeding customer expectations and meeting all applicable regulations and standards. Partnering with IONETIX provides access to cutting-edge radiopharmaceuticals and establishes a brand-differentiating service for healthcare providers